Acadia Pharmaceuticals ACAD Change in Other Liabilities
Change in Other Liabilities at other companies
Other financials
Where this comes from
Reported directly by Acadia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherOperatingLiabilities.
The official record: Acadia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Acadia Pharmaceuticals's change in other liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Acadia Pharmaceuticals's change in other liabilities?
- Acadia Pharmaceuticals (ACAD) reported change in other liabilities of -$6.5M in Q1 2026.
- How has Acadia Pharmaceuticals's change in other liabilities changed year-over-year?
- Acadia Pharmaceuticals's change in other liabilities decreased by 440.8% year-over-year, from $1.91M to -$6.5M.
- What is the long-term trend for Acadia Pharmaceuticals's change in other liabilities?
- Over 3 years (2021 to 2025), Acadia Pharmaceuticals's change in other liabilities has grown at a -16.5% compound annual growth rate (CAGR), from $1.85M to $1.08M.
- What does change in other liabilities mean?
- Change in miscellaneous liabilities affecting operating cash flow.